7,082 press releases indexed under healthcare.
Clinical outcomes from 264 PH-LHD patients demonstrate a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and sustained concurrent improvements in functional capacity, supporting the multi-dimensional therapeutic benefits of the Pulmonary...
STAMFORD, Conn., Sept. 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today announced that members of Curaleaf's executive management team will be participating in the...
Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European UnionThe Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emergeRhelion intends to leverage Filament's...
Agreement expands support for Canadian healthcare professionals and families impacted by Dravet syndrome BLAINVILLE, QC, Sept. 3, 2026 /PRNewswire/ -- Médunik Canada, a Canadian owned and operated pharmaceutical company dedicated to improving the health and quality of life of people...
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer.
Liquidia (Nasdaq: LQDA): FDA grants Fast Track designation to YUTREPIA for systemic sclerosis-associated Raynaud's phenomenon; Phase 2a study in Q4 2026
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT.
Report analyzes 12 months of provider directory audits and millions of provider records to identify systemic data quality challenges and outline a roadmap for operational improvement. LANGHORNE, Pa., Sept. 3, 2026 /PRNewswire/ -- Perspecta today announced the release of The State of...
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September.
Shanghai, China--(Newsfile Corp. - September 3, 2026) - Frost & Sullivan, in partnership with TradeGo, LeadLeo and CCXGF (China Chengxin Green Finance Technology (Beijing) Ltd.), officially unveils the 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector, delivering an in-depth panorama of the Hong-Kong 18A biotech ecosystem, capital market cycles, innovative drug R&D breakthroughs, enterprise commercialization progress and global expansion trends. The report serves...
(PR-inside.com) Cellgenic is expanding local representation and commercial support in Brazil, one of Latin America's larger healthcare and aesthetic-medicine markets. ISSCA continues to hold physician-education events in São Paulo. Activities in Brazil remain subject to applicable local law and regulatory requirements. MIAMI, FL / ACCESS Newswire / September 3, 2026 / Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that its Cellgenic division has expanded its commercial presence in Brazil through local representation, physician-facing commercial support, and related infrastructure intended to support product distribution ..